Fluclotizolam

Fluclotizolam is a thienotriazolodiazepine derivative which was first synthesised in 1979,[1] but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in 2017.[2][3][4]

Fluclotizolam
Legal status
Legal status
Identifiers
PubChem CID
Chemical and physical data
FormulaC15H10ClFN4S
Molar mass332.78 g·mol−1
3D model (JSmol)


See also

References
  1. Hellerbach J, et al. Thienotriazolodiazepine derivatives. Patent US 4155913
  2. Zawilska JB, Wojcieszak J. An expanding world of New Psychoactive Substances – Designer benzodiazepines. NeuroToxicology 2019 July; 73: 8-16. doi:10.1016/j.neuro.2019.02.015
  3. Moosmann B., Auwärter V. (2018) Designer Benzodiazepines: Another Class of New Psychoactive Substances. In: Maurer H., Brandt S. (eds) New Psychoactive Substances. Handbook of Experimental Pharmacology, vol 252. doi:10.1007/164_2018_154
  4. Chetraru E, Ameline A, Gheddar L, Raul JS, Kintz P. Les designer benzodiazepines: qu’en sait-on aujourd’hui?. Toxicologie Analytique et Clinique. 2018 Feb 1;30(1):5-18. doi:10.1016/j.toxac.2017.12.001
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.